公开(公告)号：US20230087122A1

公开(公告)日：2023-03-23

申请号：US17817877

申请日：2022-08-05

Applicant: CELLECTIS

Inventor： Jean-Pierre CABANIOLS ,  Jean-Charles EPINAT ,  Philippe DUCHATEAU

IPC: C12N15/86 ,  C12N5/0783 ,  C12N9/22 ,  C12N13/00 ,  C12N15/113 ,  C12N15/90

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.

公开(公告)号：US11603539B2

公开(公告)日：2023-03-14

申请号：US13892805

申请日：2013-05-13

Applicant: CELLECTIS

Inventor： Roman Galetto ,  Agnès Gouble ,  Stéphanie Grosse ,  Cécile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: C12N15/63 ,  C07H21/04 ,  C12N15/85 ,  A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  A61K48/00 ,  A61K39/00 ,  A61K38/00

Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20230050345A1

公开(公告)日：2023-02-16

申请号：US17715218

申请日：2022-04-07

Applicant: CELLECTIS

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cécile SCHIFFER-MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: A61K35/17 ,  C12N5/0783 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C12N15/85

Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20220233588A1

公开(公告)日：2022-07-28

申请号：US16625678

申请日：2018-07-02

Applicant: CELLECTIS

Inventor： David SOURDIVE ,  Aymeric DUCLERT ,  Mathieu SIMON ,  Philippe DUCHATEAU ,  Alan Marc WILLIAMS ,  Laurent POIROT

IPC: A61K35/17 ,  C12Q1/6881

Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

公开(公告)号：US20220177914A1

公开(公告)日：2022-06-09

申请号：US17674436

申请日：2022-02-17

Applicant: Cellectis

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cecile MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: C12N15/85 ,  A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US11311575B2

公开(公告)日：2022-04-26

申请号：US14894426

申请日：2014-05-13

Applicant: CELLECTIS

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cécile Schiffer-Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: A61K48/00 ,  C07H21/04 ,  A61K35/17 ,  C12N9/22 ,  C12N5/0783 ,  A01K67/00 ,  A61K35/12

Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US11274316B2

公开(公告)日：2022-03-15

申请号：US17198505

申请日：2021-03-11

Applicant: Cellectis

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cecile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: C12N15/85 ,  A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  A61K39/00 ,  A61K38/00

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US11136566B2

公开(公告)日：2021-10-05

申请号：US16237901

申请日：2019-01-02

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Alexandre Juillerat ,  Julien Valton ,  Claudia Bertonati ,  Jean-Charles Epinat ,  George H. Silva

IPC: C12N9/16 ,  C12N15/63 ,  C12N5/071 ,  C12N5/10 ,  C07K14/195 ,  C12N9/22 ,  C07K14/47 ,  A61K38/00 ,  C12P19/34

Abstract: The present invention relates to new Transcription Activator-Like Effector proteins and more particularly new Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process nucleic acids. The present invention also concerns methods to use these new Transcription Activator-Like Effector proteins. The present invention also relates to vectors, compositions and kits in which Transcription Activator-Like Effector proteins of the present invention are used.

公开(公告)号：US20210277411A1

公开(公告)日：2021-09-09

申请号：US17259456

申请日：2019-07-09

Applicant: CELLECTIS

Inventor： Wenzheng ZHANG ,  Feng ZHANG

IPC: C12N15/82

Abstract: Materials and methods for creating canola (e.g., Brassica napus) lines having oil with increased oleic acid content are provided herein.

公开(公告)号：US11077144B2

公开(公告)日：2021-08-03

申请号：US17099608

申请日：2020-11-16

Applicant: Cellectis

Inventor： Roman Galetto ,  Julianne Smith ,  Andrew Scharenberg ,  Cécile Schiffer-Mannioui

IPC: A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  A61K39/00 ,  A61K38/00

Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.